Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology (28% of 2024 revenues), which develops products for the development of therapeutics; life sciences (31% of 2024 revenues), which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics (41% of 2024 revenues), which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DHR | DANAHER CORP /DE/ | 2026-09-08 14:59:59 | 205.31 | -2.33 | -1.12 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DHR | 0000313616 | DANAHER CORP /DE/ | US2358511028 | S4BKK9OTCEWQ3YHPFM11 | 591995548 | NYSE | 3823 | Industrial Instruments For Measurement, Display, and Control | 1231 | DE | 2200 PENNSYLVANIA AVE. N.W. | WASHINGTON | DC | 20037-1701 | UNITED STATES | US | 2028280850 | 2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC, 20037-1701 | 2200 PENNSYLVANIA AVE. N.W., WASHINGTON, DC, 20037-1701 | — | Healthcare industry | 1969 | Rainer Blair | 63,000 | https://www.danaher.com/ | 125,900,000,000 | 888,200,000 | 702,986,054 | Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology (28% of 2024 revenues), which develops products for the development of therapeutics; life sciences (31% of 2024 revenues), which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics (41% of 2024 revenues), which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing. | 2026-09-03 18:10:40 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 125,900,000,000 | -35,200,000,000 | -21.8498 | 707,139,356 | -7,570,496 | -1.0592 |
| 2024 | 161,100,000,000 | 3,000,000,000 | 1.8975 | 714,709,852 | -24,991,873 | -3.3786 |
| 2023 | 158,100,000,000 | -9,200,000,000 | -5.4991 | 739,701,725 | 11,124,839 | 1.5269 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Christopher P. Riley | Executive Vice President | 2025 | 848,000 | 0 | 4,425,309 | 1,587,880 | 100,192 | 11,255,848 |
| Julie Sawyer | Executive Vice President | 2025 | 848,000 | 0 | 4,425,309 | 1,587,880 | 139,623 | 11,295,279 |
| Rainer M. Blair | President, CEO | 2025 | 1,400,000 | 0 | 9,292,370 | 4,194,400 | 521,853 | 23,795,280 |
| Matthew R. Mcgrew | CFO, Executive Vice President | 2025 | 1,005,330 | 0 | 2,519,058 | 1,882,480 | 287,114 | 7,967,519 |
| Jose-Carlos Gutierrez-Ramos | Senior Vice President | 2025 | 888,460 | 0 | 1,959,422 | 1,530,550 | 97,016 | 6,243,771 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 60,000 |
| 2024 | 63,000 |
| 2023 | 63,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 24,568,000,000 | 23,875,000,000 | 23,890,000,000 |
| Cost Of Revenue | 10,045,000,000 | 9,669,000,000 | 9,856,000,000 |
| Gross Profit | 14,523,000,000 | 14,206,000,000 | 14,034,000,000 |
| Research And Development Expenses | 1,598,000,000 | 1,584,000,000 | 1,503,000,000 |
| General And Administrative Expenses | 8,235,000,000 | 7,759,000,000 | 7,329,000,000 |
| Operating Expenses | 9,833,000,000 | 9,343,000,000 | 8,832,000,000 |
| Operating Income | 4,690,000,000 | 4,863,000,000 | 5,202,000,000 |
| Net Income | 3,614,000,000 | 3,899,000,000 | 4,764,000,000 |
| Earnings Per Share Basic | 5.07 | 5.33 | 6.44 |
| Earnings Per Share Diluted | 5.05 | 5.29 | 6.38 |
| Weighted Average Shares Outstanding Basic | 712,700,000 | 731,000,000 | 736,500,000 |
| Weighted Average Shares Outstanding Diluted | 716,100,000 | 737,200,000 | 743,100,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 4,615,000,000 | 2,078,000,000 | 5,864,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 3,913,000,000 | 3,537,000,000 | 3,922,000,000 |
| Inventories | 2,489,000,000 | 2,330,000,000 | 2,594,000,000 |
| Non Trade Receivables | 989,000,000 | 853,000,000 | 715,000,000 |
| Other Assets Current | 1,739,000,000 | 1,552,000,000 | 1,557,000,000 |
| Total Assets Current | 12,756,000,000 | 9,497,000,000 | 13,937,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 5,531,000,000 | 4,990,000,000 | 4,553,000,000 |
| Other Assets Non Current | 4,209,000,000 | 3,990,000,000 | 3,644,000,000 |
| Total Assets Non Current | 70,708,000,000 | 68,045,000,000 | 70,551,000,000 |
| Total Assets | 83,464,000,000 | 77,542,000,000 | 84,488,000,000 |
| Accounts Payable | 1,844,000,000 | 1,753,000,000 | 1,766,000,000 |
| Deferred Revenue | 1,353,000,000 | 1,299,000,000 | 1,465,000,000 |
| Short Term Debt | 2,000,000 | 505,000,000 | 1,695,000,000 |
| Other Liabilities Current | 4,961,000,000 | 4,540,000,000 | 4,813,000,000 |
| Total Liabilities Current | 6,807,000,000 | 6,798,000,000 | 8,274,000,000 |
| Long Term Debt | 18,418,000,000 | 16,005,000,000 | 18,402,000,000 |
| Other Liabilities Non Current | 5,700,000,000 | 5,694,000,000 | 6,017,000,000 |
| Total Liabilities Non Current | 24,123,000,000 | 21,201,000,000 | 22,728,000,000 |
| Total Liabilities | 30,930,000,000 | 27,999,000,000 | 31,002,000,000 |
| Common Stock | 9,000,000 | 9,000,000 | 9,000,000 |
| Retained Earnings | 46,891,000,000 | 44,188,000,000 | 41,074,000,000 |
| Accumulated Other Comprehensive Income | -207,000,000 | -3,218,000,000 | -1,748,000,000 |
| Total Shareholders Equity | 52,534,000,000 | 49,543,000,000 | 53,486,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 750,000,000 | 721,000,000 | 2,166,000,000 |
| Share Based Compensation Expense | 298,000,000 | 288,000,000 | 306,000,000 |
| Other Non Cash Income Expense | 11,000,000 | — | — |
| Change In Accounts Receivable | 216,000,000 | -331,000,000 | -322,000,000 |
| Change In Inventories | 58,000,000 | -147,000,000 | -185,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | 55,000,000 | -274,000,000 | -419,000,000 |
| Change In Accounts Payable | 9,000,000 | 19,000,000 | -149,000,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 6,416,000,000 | 6,688,000,000 | 7,164,000,000 |
| Purchases Of Marketable Securities | 127,000,000 | 331,000,000 | 172,000,000 |
| Sales Of Marketable Securities | 12,000,000 | 253,000,000 | 61,000,000 |
| Acquisition Of Property Plant And Equipment | 1,156,000,000 | 1,392,000,000 | 1,383,000,000 |
| Acquisition Of Business | 0 | 558,000,000 | 5,610,000,000 |
| Other Investing Activities | -33,000,000 | -34,000,000 | -44,000,000 |
| Cash From Investing Activities | -1,196,000,000 | -1,981,000,000 | -7,081,000,000 |
| Tax Withholding For Share Based Compensation | 69,000,000 | 97,000,000 | 80,000,000 |
| Payments Of Dividends | 878,000,000 | 768,000,000 | 821,000,000 |
| Issuance Of Common Stock | 85,000,000 | 162,000,000 | 68,000,000 |
| Repurchase Of Common Stock | 3,088,000,000 | 5,979,000,000 | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | -125,000,000 | -131,000,000 | -67,000,000 |
| Cash From Financing Activities | -2,961,000,000 | -8,385,000,000 | -273,000,000 |
| Change In Cash | 2,537,000,000 | -3,786,000,000 | -131,000,000 |
| Cash At End Of Period | 4,615,000,000 | 2,078,000,000 | 5,864,000,000 |
| Income Taxes Paid | 1,200,000,000 | 1,300,000,000 | 1,800,000,000 |
| Interest Paid | 331,000,000 | 370,000,000 | 392,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 5.07 | 5.33 | 6.44 |
| Price To Earnings Ratio | 45.1519 | 43.0675 | 35.9224 |
| Earnings Growth Rate | -4.878 | -17.236 | -34.2857 |
| Price Earnings To Growth Ratio | -9.2561 | -2.4987 | -1.0477 |
| Book Value Per Share | 73.7112 | 67.7743 | 72.6219 |
| Price To Book Ratio | 3.1056 | 3.387 | 3.1855 |
| Ebitda | 5,829,000,000 | 6,198,000,000 | 9,016,000,000 |
| Enterprise Value | 176,956,284,000 | 182,233,050,000 | 184,614,910,000 |
| Dividend Yield | 0.0054 | 0.0046 | 0.0048 |
| Dividend Payout Ratio | 0.2429 | 0.197 | 0.1723 |
| Debt To Equity Ratio | 0.3506 | 0.3332 | 0.3757 |
| Capital Expenditures | 1,291,000,000 | 1,158,000,000 | 2,763,000,000 |
| Free Cash Flow | 5,125,000,000 | 5,530,000,000 | 4,401,000,000 |
| Return On Equity | 0.0688 | 0.0787 | 0.0891 |
| One Year Beta | 0.9271 | 0.6639 | 0.9034 |
| Three Year Beta | 0.858 | 0.9611 | 0.9521 |
| Five Year Beta | 0.9118 | 0.8383 | 0.8612 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Blair Rainer | Director, President & CEO | 2026-08-21 | 11,307 | D | 46,948 |
| Blair Rainer | Director, President & CEO | 2026-08-21 | 39,193 | D | 7,755 |
| Blair Rainer | Director, President & CEO | 2026-08-21 | 7,755 | D | 0 |
| RALES STEVEN M | Director, Chairman | 2026-08-04 | 500,000 | A | 3,605,808 |
| RALES STEVEN M | Director, Chairman | 2026-08-04 | 1,000,000 | A | 1,000,000 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Alan Armstrong | Senator | 2026-07-21 | Purchase | 2026-03-27 | Self | $1,001 - $15,000 |
| Sheldon Whitehouse | Senator | 2025-09-03 | Sale (Full) | 2025-08-28 | Self | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-02-27 | Sale (Full) | 2025-02-13 | Joint | $15,001 - $50,000 |
| Sheldon Whitehouse | Senator | 2024-05-20 | Sale (Full) | 2024-04-09 | Spouse | $15,001 - $50,000 |
| Markwayne Mullin | Senator | 2023-10-12 | Purchase | 2023-09-13 | Joint | $15,001 - $50,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Julie Johnson | 2026-01-15 | TX32 | Sale | 2025-12-18 | Joint | $1,001 - $15,000 |
| Julia Letlow | 2026-01-13 | LA05 | Purchase | 2025-04-28 | — | $1,001 - $15,000 |
| Julie Johnson | 2025-12-11 | TX32 | Sale (Partial) | 2025-11-13 | Joint | $1,001 - $15,000 |
| Julie Johnson | 2025-11-14 | TX32 | Purchase | 2025-10-07 | Joint | $1,001 - $15,000 |
| Lisa McClain | 2025-10-22 | MI09 | Sale | 2025-09-25 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Parkside Financial Bank & Trust | 2026-06-30 | 788,208 | 4,138 | 190.4804 |
| Allianz Asset Management GmbH | 2026-06-30 | 12,533,584 | 65,800 | 190.48 |
| Allianz Asset Management GmbH | 2026-06-30 | 8,647,792 | 45,400 | 190.48 |
| Allianz Asset Management GmbH | 2026-06-30 | 12,435,677 | 65,286 | 190.48 |
| BROWN, LISLE/CUMMINGS, INC. | 2026-06-30 | 242,291 | 1,272 | 190.4803 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| STERLING CAPITAL FUNDS | 2026-06-30 | Class R6 | STRSX | 41,441 | 7,893,681.68 | 2.262 |
| STERLING CAPITAL FUNDS | 2026-06-30 | C CLASS | BOPCX | 41,441 | 7,893,681.68 | 2.262 |
| STERLING CAPITAL FUNDS | 2026-06-30 | A CLASS | BOPAX | 41,441 | 7,893,681.68 | 2.262 |
| STERLING CAPITAL FUNDS | 2026-06-30 | INSTITUTIONAL CLASS | BOPIX | 41,441 | 7,893,681.68 | 2.262 |
| WEITZ FUNDS | 2026-06-30 | Partners III Opportunity Fund - Investor Class | WPOIX | 90,000 | 17,143,200 | 5.1293 |